Abstract: The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.

Abstract: The present invention relates to cardio- and renosafe antidiabetic therapy.

Abstract: The present invention relates to cardio-safe antidiabetic therapy

Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.

Abstract: A fluid cargo handling system includes a quick release manifold system mounted on a floating marine platform. The quick release manifold system has a first valve in fluid communication with the first end of a first fluid transfer hose to control fluid flow within the first fluid transfer hose. A first coupler is attached to the first valve. The first coupler has a first port in fluid communication with the first valve, a second port, a purging fluid inlet and a waste fluid outlet. A drain tank is in fluid communication with the first coupler via the waste fluid outlet, and a pressurized fluid source carried is in fluid communication with the first coupler via the purging fluid inlet.

Abstract: A fluid cargo handling system includes a marine manifold tower system and a floating marine platform on which is carried a liquid manifold assembly which is coupled to a cryogenic liquid transfer hose extending from the floating marine platform to the marine manifold tower system. The cryogenic liquid transfer hose is also connected to a cryogenic hose manifold assembly mounted on the marine manifold tower system. The marine manifold tower system includes an elongated tower having a first end secured to the seabed and a second end supporting the cryogenic hose manifold assembly, elevating the cryogenic hose manifold assembly above the water surface. The floating marine platform moves between a first position adjacent the marine manifold tower system and a second position, spaced apart from the marine manifold tower system, where the floating marine platform is in fluid communication with a fluid cargo transport vessel.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract: The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.

Abstract: The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.

Abstract: A fluid cargo handling system includes a marine manifold tower system and a floating marine platform on which is carried a liquid manifold assembly which is coupled to a cryogenic liquid transfer hose extending from the floating marine platform to the marine manifold tower system. The cryogenic liquid transfer hose is also connected to a cryogenic hose manifold assembly mounted on the marine manifold tower system. The marine manifold tower system includes an elongated tower having a first end secured to the seabed and a second end supporting the cryogenic hose manifold assembly, elevating the cryogenic hose manifold assembly above the water surface. The floating marine platform moves between a first position adjacent the marine manifold tower system and a second position, spaced apart from the marine manifold tower system, where the floating marine platform is in fluid communication with a fluid cargo transport vessel.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract: A fluid cargo handling system with a standoff system includes a floating marine platform having an elongated first platform side, an elongated second platform side and a buoyant hull with a hull bottom. A fluid cargo transfer hose is carried on a hose reel mounted on the platform. A drive system maintains the marine platform at an offset distance from another marine platform, preventing physical contact therebetween. The drive system has at least two drive devices adjacent the first platform side and at least two drive devices adjacent the second platform side, with each of the drive devices along the first side engaging a separate driveline extending from the hull bottom adjacent the first side towards the second platform side and each of the drive devices along the second side engaging a separate driveline extending from the hull bottom adjacent the second side towards the first platform side.

Abstract: A fluid cargo handling system includes a quick release manifold system mounted on a floating marine platform. The quick release manifold system has a first valve in fluid communication with the first end of a first fluid transfer hose to control fluid flow within the first fluid transfer hose. A first coupler is attached to the first valve. The first coupler has a first port in fluid communication with the first valve, a second port, a purging fluid inlet and a waste fluid outlet. A drain tank is in fluid communication with the first coupler via the waste fluid outlet, and a pressurized fluid source carried is in fluid communication with the first coupler via the purging fluid inlet.

Abstract: A fluid cargo handling system with a standoff system includes a floating marine platform having an elongated first platform side, an elongated second platform side and a buoyant hull with a hull bottom. A fluid cargo transfer hose is carried on a hose reel mounted on the platform. A drive system maintains the marine platform at an offset distance from another marine platform, preventing physical contact therebetween. The drive system has at least two drive devices adjacent the first platform side and at least two drive devices adjacent the second platform side, with each of the drive devices along the first side engaging a separate driveline extending from the hull bottom adjacent the first side towards the second platform side and each of the drive devices along the second side engaging a separate driveline extending from the hull bottom adjacent the second side towards the first platform side.

Abstract: A fluid cargo handling system includes a marine manifold tower system and a floating marine platform on which is carried a liquid manifold assembly which is coupled to a cryogenic liquid transfer hose extending from the floating marine platform to the marine manifold tower system. The cryogenic liquid transfer hose is also connected to a cryogenic hose manifold assembly mounted on the marine manifold tower system. The marine manifold tower system includes an elongated tower having a first end secured to the seabed and a second end supporting the cryogenic hose manifold assembly, elevating the cryogenic hose manifold assembly above the water surface. The floating marine platform moves between a first position adjacent the marine manifold tower system and a second position, spaced apart from the marine manifold tower system, where the floating marine platform is in fluid communication with a fluid cargo transport vessel.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.